Predictive value of peripheral blood lymphocyte subsets for children with intravenous immunoglobulin-resistant Kawasaki disease
XUE Yan, YIN Jing, XU Li, DANG Li-Heng, WANG Chao, CUI Ya-Qiong, ZHANG Xin-Jie, LI Chong-Wei
Department of Rheumatology & Immunology, Tianjin Children's Hospital (Children's Hospital of Tianjin University), Tianjin 300134, China (Li C-W, Email: leechongwei@126.com)
Abstract:Objective Based on peripheral blood lymphocyte subsets and common laboratory test indexes, this study aimed to construct a predictive scoring system for intravenous immunoglobulin (IVIG)-resistant Kawasaki disease (KD). Methods Children hospitalized in Tianjin Children's Hospital from January 2021 to March 2023 were included in the study (185 cases of IVIG-sensitive KD and 41 cases of IVIG -resistant KD). Forty-six healthy children matched for age and gender were selected as controls. The relative percentage and absolute counts of peripheral lymphocyte subsets were measured by flow cytometry. Multivariate logistic regression was used to identify the predictive factors for IVIG-resistant KD and to construct a predictive scoring system for predicting IVIG-resistant KD. Results The multivariate logistic regression analysis showed that CD4+ T cell absolute count, natural killer cell absolute count, serum sodium level, globulin level, and total bilirubin level were identified as predictive factors for IVIG-resistant KD (P<0.05). The predictive scoring system based on these factors achieved a sensitivity of 70.7% and a specificity of 83.8% in predicting IVIG-resistant KD. Conclusions Peripheral blood lymphocyte subsets can serve as predictive indicators for IVIG-resistant KD in children. The introduction of this indicator and the establishment of a scoring system based on it can provide a higher accuracy in predicting IVIG-resistant KD in children.
XUE Yan,YIN Jing,XU Li et al. Predictive value of peripheral blood lymphocyte subsets for children with intravenous immunoglobulin-resistant Kawasaki disease[J]. CJCP, 2023, 25(12): 1211-1218.
Ae R, Abrams JY, Maddox RA, et al. Corticosteroids added to initial intravenous immunoglobulin treatment for the prevention of coronary artery abnormalities in high-risk patients with Kawasaki disease[J]. J Am Heart Assoc, 2020, 9(17): e015308. PMID: 32811256. PMCID: PMC7660775. DOI: 10.1161/JAHA.119.015308.
Hamada H, Suzuki H, Onouchi Y, et al. Efficacy of primary treatment with immunoglobulin plus ciclosporin for prevention of coronary artery abnormalities in patients with Kawasaki disease predicted to be at increased risk of non-response to intravenous immunoglobulin (KAICA): a randomised controlled, open-label, blinded-endpoints, phase 3 trial[J]. Lancet, 2019, 393(10176): 1128-1137. PMID: 30853151. DOI: 10.1016/S0140-6736(18)32003-8.
Noval Rivas M, Lee Y, Wakita D, et al. CD8+ T cells contribute to the development of coronary arteritis in the Lactobacillus casei cell wall extract-induced murine model of Kawasaki disease[J]. Arthritis Rheumatol, 2017, 69(2): 410-421. PMID: 27696768. PMCID: PMC5274597. DOI: 10.1002/art.39939.
McCrindle BW, Rowley AH, Newburger JW, et al. Diagnosis, treatment, and long-term management of Kawasaki disease: a scientific statement for health professionals from the American Heart Association[J]. Circulation, 2017, 135(17): e927-e999. PMID: 28356445. DOI: 10.1161/CIR.0000000000000484.
Kobayashi T, Inoue Y, Takeuchi K, et al. Prediction of intravenous immunoglobulin unresponsiveness in patients with Kawasaki disease[J]. Circulation, 2006, 113(22): 2606-2612. PMID: 16735679. DOI: 10.1161/CIRCULATIONAHA.105.592865.
Egami K, Muta H, Ishii M, et al. Prediction of resistance to intravenous immunoglobulin treatment in patients with Kawasaki disease[J]. J Pediatr, 2006, 149(2): 237-240. PMID: 16887442. DOI: 10.1016/j.jpeds.2006.03.050.
Sano T, Kurotobi S, Matsuzaki K, et al. Prediction of non-responsiveness to standard high-dose gamma-globulin therapy in patients with acute Kawasaki disease before starting initial treatment[J]. Eur J Pediatr, 2007, 166(2): 131-137. PMID: 16896641. DOI: 10.1007/s00431-006-0223-z.
Yang S, Song R, Zhang J, et al. Predictive tool for intravenous immunoglobulin resistance of Kawasaki disease in Beijing[J]. Arch Dis Child, 2019, 104(3): 262-267. PMID: 30026252. DOI: 10.1136/archdischild-2017-314512.
Wu S, Liao Y, Sun Y, et al. Prediction of intravenous immunoglobulin resistance in Kawasaki disease in children[J]. World J Pediatr, 2020, 16(6): 607-613. PMID: 32232677. DOI: 10.1007/s12519-020-00348-2.
Matsuguma C, Wakiguchi H, Suzuki Y, et al. Dynamics of immunocyte activation during intravenous immunoglobulin treatment in Kawasaki disease[J]. Scand J Rheumatol, 2019, 48(6): 491-496. PMID: 31272272. DOI: 10.1080/03009742.2019.1604992.
Zhang C, Zhang X, Shen J, et al. Changes in peripheral blood neutrophils, lymphocytes and IL-10 in children with Kawasaki disease from different age groups undergoing intravenous immunoglobulin: a retrospective study[J]. Mediators Inflamm, 2020, 2020: 5213451. PMID: 33293897. PMCID: PMC7691014. DOI: 10.1155/2020/5213451.
Choi IS, Lee MJ, Choi SA, et al. Circulating immune cell profile and changes in intravenous immunoglobulin responsiveness over the disease course in children with Kawasaki disease[J]. Front Pediatr, 2022, 9: 792870. PMID: 35186822. PMCID: PMC8855096. DOI: 10.3389/fped.2021.792870.